Trimethoprim: Novel Reactive Intermediates and Bioactivation Pathways by Cytochrome P450s
- 25 September 2008
- journal article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 21 (11), 2181-2187
- https://doi.org/10.1021/tx8002593
Abstract
Trimethoprim (TMP) is a widely used antibacterial agent that is usually considered as a safe drug. TMP has, however, been implicated in rare adverse drug reactions (ADRs) in humans. Bioactivation to a reactive iminoquinone methide intermediate has been proposed as a possible cause for the toxicity of the drug. However, little is known about the cytochrome P450s (P450s) involved in this bioactivation and in the metabolism of TMP in general. In this study, we have investigated the metabolism and bioactivation of TMP by human liver microsomes (HLM) and rat liver microsomes, by recombinant human cytochrome P450s, and by the bacterial P450 BM3 mutant M11his. In addition to non GSH-dependent metabolites, five GSH adducts were identified in the HLM incubations. Next to two major GSH adducts probably originating from the iminoquinone methide intermediate described previously, three minor GSH adducts were also identified, indicating that other types of reactive intermediates are formed by HLM, such as ortho-quinones and para-quinone methide intermediates. The major GSH adducts were produced by P450 1A2 and P450 3A4, while the minor GSH adducts were mainly formed by P450 1A2, P450 3A4, and P450 2D6. Although preliminary, these results might implicate that genetic polymorphisms in P450 enzymes could play a role in the onset of TMP-related ADRs in humans.Keywords
This publication has 18 references indexed in Scilit:
- The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsBritish Journal of Clinical Pharmacology, 2004
- Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.Drug Metabolism and Disposition, 2002
- Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivityPharmacogenetics, 2000
- Trimethoprim‐sulphamethoxazole‐associated blood dyscrasias. Ten years'experience of the Swedish spontaneous reporting systemJournal of Internal Medicine, 1990
- Oral Therapy forPneumocystis cariniiPneumonia in the Acquired Immunodeficiency SyndromeThe New England Journal of Medicine, 1990
- Drug points: Toxic epidermal necrolysis and trimethoprimBMJ, 1988
- Toxic epidermal necrolysis occurring during treatment with trimethoprim aloneBMJ, 1988
- Clinical Experience with Adverse Reactions to Trimethoprim-SulfamethoxazoleThe Journal of Infectious Diseases, 1973
- Determination of Trimethoprim and its N-oxide Metabolites in Urine of Man, Dog, and Rat by Differential Pulse PolarographyJournal of Pharmaceutical Sciences, 1973
- Studies on Sulfamethoxazole/Trimethoprim. Absorption, Distribution, Excretion and Metabolism of Trimethoprim in RatCHEMICAL & PHARMACEUTICAL BULLETIN, 1972